iTeos Therapeutics (NASDAQ:ITOS) Stock Rating Reaffirmed by HC Wainwright

iTeos Therapeutics (NASDAQ:ITOS – Get Rating)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $54.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 282.44% from the company’s previous close.

ITOS has been the subject of several other reports. Wedbush lowered their price target on shares of iTeos Therapeutics from $45.00 to $33.00 and set an “outperform” rating for the company in a research note on Thursday. JPMorgan Chase & Co. lowered their price target on shares of iTeos Therapeutics from $34.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday.

iTeos Therapeutics Stock Down 4.4 %

iTeos Therapeutics stock opened at $14.12 on Friday. The company has a market capitalization of $502.39 million, a PE ratio of 5.49 and a beta of 1.42. The firm has a fifty day simple moving average of $18.81 and a two-hundred day simple moving average of $19.40. iTeos Therapeutics has a twelve month low of $13.81 and a twelve month high of $37.26.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ITOS. BlackRock Inc. raised its stake in shares of iTeos Therapeutics by 106.5% during the first quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock valued at $107,203,000 after acquiring an additional 1,718,085 shares during the last quarter. State Street Corp increased its position in shares of iTeos Therapeutics by 124.3% during the first quarter. State Street Corp now owns 1,711,891 shares of the company’s stock valued at $55,089,000 after buying an additional 948,540 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of iTeos Therapeutics during the third quarter valued at about $8,883,000. Vanguard Group Inc. increased its position in shares of iTeos Therapeutics by 39.1% during the first quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock valued at $47,499,000 after buying an additional 415,232 shares during the period. Finally, Saturn V Capital Management LLC purchased a new position in shares of iTeos Therapeutics during the fourth quarter valued at about $7,028,000.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.